---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-037885"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:35:47.164202+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma appoints Pasha Sarraf to board of directors

## Summary
- Pasha Sarraf appointed to board on March 10, 2025.
- Granted option to purchase 48,800 shares vesting over three years.
- Compensation per Company's Director Compensation Policy.
- Entered standard indemnification agreement for director service.
- No arrangements or transactions between Sarraf and Company.

## SEC filing metadata
- accession: 0000950170-25-037885
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095017025037885/0000950170-25-037885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095017025037885/cue-20250310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-037885
- JSON: https://secwatch.observer/filing/0000950170-25-037885.json
- Plain text: https://secwatch.observer/filing/0000950170-25-037885.txt

## Key facts
- Executive change
  Pasha Sarraf was appointed as member of the board of directors at Cue Biopharma, Inc..
  - Action: appointed
  - Role: member of the board of directors
  source text: On March 10, 2025, Pasha Sarraf was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc. (the “Company”), following the recommendation of the Corporate Governance and Nominating Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000095017025037885/0000950170-25-037885-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.